PHOTO
- The conference unveiled pioneering treatments of world-leading experts, which will be accessible to UAE patients
Dubai: King’s College Hospital London in Dubai launched, a two-day medical conference at the Address Hotel Dubai Mall today. His Excellency Humaid Al Qutami, Director-General of the Dubai Health Authority inaugurated the conference, which unveiled the first of its kind vaccine for the treatment of leukaemia, amongst other pioneering works of world-leading experts.
His Excellency Al Qutami commended King’s College Hospital London’s efforts for bringing frontrunning expertise to the people of the emirate, and highlighted DHA’s strategy to guide and support reputed private healthcare providers, such as King’s, in building sustainable healthcare public-private partnership models in Dubai.
His excellency also explained that the Authority is implementing a clear policy to promote the promising investment opportunities in the health sector in Dubai, and thus attract more hospitals, international health centers, and more expertise and medical competencies in various fields. He also highlighted that the authority will be introducing a set of smart systems to promote the development of the private health sectors in Dubai.
H.E. Ahmed H. Al Tayer, Chairman of King’s College Hospital London in the UAE, welcomed eight distinguished world-class professors, who revealed the latest ground-breaking medical advancements in their field.
Ghulam Mufti, Professor of Haematological Oncology, at King’s College Hospital London in the UK, presented the latest advancement in the treatment of blood cancers (two of the most debilitating blood cancers – B-cell acute lymphoblastic leukaemia and high-grade B-cell lymphoma) through CAR-T cell therapy, a cellular therapy which acts like a vaccine. In the treatment of leukaemia, cellular therapy aims to improve the immune system's ability to seek out and fight leukaemia cells, for those patients who unfortunately relapse. To create this vaccine, immune cells (T cells) from a patient’s blood are manipulated within the laboratory and made to adopt genes that effectively recognise and destroy the cancer cells.
This therapy, which is approved for use on the NHS in England[1][2], was the world’s first study of its type to treat patients with leukaemia, who relapsed after cancer treatment or stem cell transplant[3], differently. Patients in the UAE in the near future will be able to access this therapy through King’s clinical pathway*. Mr Christian Schuhmacher, Chief Executive Officer of King’s College Hospital London in the UAE, said: “Bringing pioneering medical advancements, such as this, truly brings to life our long-standing commitment to the UAE, and its people.”
The two-day event aims to present the latest evidence in the management and treatment of other common medical problems in the UAE, notably in cardiovascular disease, chronic liver disease, including liver transplant, the endoscopic and surgical management of diabetes and metabolic disease, genetics, pain management, weight management, women’s health, as well as antimicrobial stewardship.
Other ground-breaking medical advancements unveiled also include various techniques, developed by the world-renowned fetal medicine pioneer, Kypros Nicolaides, Professor of Fetal Medicine, at King’s College Hospital London in the UK. These techniques are designed to diagnose complications of the fetus and treat an unborn child in the womb. Some of these innovative techniques include inserting a little balloon through the throat of a fetus with a congenital opening in the diaphragm, allowing for normal lung development, or predicting whether a mother will develop pre-eclampsia – a condition developed in pregnancy characterised by high blood pressure, which can be fatal for both the mother and her child, and preventing it[4].
Dr. Gowri Ramanathan, Chief Medical Officer at King’s College Hospital London in Dubai, who is also Conference Chair, said: “Thanks to our seamless integration with our mother hospital, King’s in London, and our London Faculty Programme, we are able to provide UAE patients with an unmatched care pathway. They can access world-class experts from not just King’s in London, but also all the specialists from other leading hospitals and clinical research centres in the UK that are part of King’s Health Partners network.”
Kings’ medical conference, which is free of cost to students, will continue on March 22nd with CME accredited plenary lectures and talks, presentations by renowned speakers from the UK and the UAE, interactive sessions and case study discussions in chronic liver disease, antimicrobial stewardship and genetics. To register, healthcare professionals or students may visit www.kingscollege.menaconference.com .
-Ends-
*King’s patient pathway is the journey that patients go through from diagnosis, to treatment and post treatment care. For patients seeking tertiary care or complex procedures, which are not yet available in the UAE, but are conducted at King’s in London, King’s in the UAE will seamlessly facilitate the patient referrals in the UK.
Media contact: Alia Karim, Hill+Knowlton Strategies:
0565019503 or
Alia.Karim@hkstrategies.com
About King’s College Hospital London in the United Arab Emirates
The world-renowned British teaching hospital King’s College Hospital London, is now providing trusted patient care in the UAE after a joint venture with Al Tayer Group, Dubai Investments and UK-based Ashmore Group.
King’s College Hospital London has three operational medical centres in the UAE; one in Dubai Marina that opened in August 2018, another one in Jumeirah that opened in September 2017, and the third in Abu Dhabi which has been operational since 2014.
King’s is expanding its UAE footprint with the recent opening of its flagship Dubai based hospital, in Dubai Hills. The hospital will focus on many specialties including obstetrics and gynaecology, paediatrics, orthopaedics, neurology, plastic surgery, endocrinology, cardiology, family medicine and other specialities. For more information or to book an appointment please call +971 4 519 9999 (Dubai Hills), +971 2 501 4000 (Abu Dhabi), +971 4 378 9555 (Jumeirah), +971 4 581 3222 (Marina) or visit www.kch.ae
About King’s College Hospital, London: King’s College Hospital NHS Foundation Trust is one of the UK’s largest and busiest teaching hospitals, with 11,000 staff and providing over 1m patient contacts every year. 9,500 babies are delivered by our hospitals each year, and over 750 patients come to our Emergency Departments every day. The hospital also trains over 900 dentists, 750 doctors and 300 nurses every year and is part of Kings Academic Partnership, leading on clinical research and academic excellence across a range of disciplines. The Trust is recognised in the UK for its leading position across a full range of capabilities and is also recognised internationally for its work in liver disease and transplantation (Europe’s largest liver transplantation centre), neurosciences, cardiac, haemato-oncology, stroke and major trauma. For more information, please visit http://www.kch.nhs.uk/
King’s College Hospital also provides treatment to private patients from outside the UK.
About Ashmore:
Ashmore is a specialist emerging markets investment manager with over 25 years’ experience in these markets. Based in London, the business was founded in 1992 as part of the Australia and New Zealand Banking Group. In 1999, Ashmore became independent and today manages USD 76.7 billion (at 31st December 2018) in pooled funds, segregated accounts and structured products.
Ashmore offers several emerging markets investment themes including fixed income, equities, alternatives, multi-asset and overlay/liquidity. Ashmore’s clients include sovereign wealth funds, central banks, pension funds, institutions and high net worth individuals.
For more information, please visit www.ashmoregroup.com.
About Al Tayer Group:
Al Tayer Group is a diversified regional business established in 1979 with its headquarters in Dubai, UAE. Since its inception, the Group has grown rapidly and currently operates in 6 countries in the Middle-East and beyond, with nearly 9,000 employees.
Al Tayer Group operates leading, quality-focused businesses in automobile sales and service, luxury and lifestyle retail, perfumes and cosmetics distribution, real estate, engineering and interior contracting. The Group’s portfolio includes several of the world’s leading brands such as Armani, Bvlgari, Banana Republic, Gap, Harvey Nichols, Bloomingdale’s, Aveda, Kiehl’s, Ford, Ferrari, Jaguar, Land Rover and Maserati. The Group operates nearly 200 retail stores across multiple markets in the Middle East. In addition, Al Tayer Group has investments in contracting, supply chain management, precision tools manufacturing, cinemas exhibitions, and travel agency services.
The Group’s value system is committed to excellence in delivering quality and customer service by empowering employees, celebrating diversity and encouraging thought leadership, within an ethics-driven corporate culture. The Group supports various charities and is the patron of many initiatives which grant children access to quality education and future opportunities. For more information on Al Tayer Group, please visit www.altayer.com
About Dubai Investments PJSC: Dubai Investments PJSC is a diversified investment company listed on the Dubai Financial Market, with over 16,700 shareholders and a market capitalization of approximately AED 6.8 billion. Dubai Investments currently has 35 subsidiaries and joint ventures across 23 diverse sectors. Incorporated in 1995, Dubai Investments operates in the core sectors of real estate and building materials and manufacturing, with investments in growth areas including education, healthcare and others as part of its strategic expansion plans. For more information, please visit www.dubaiinvestments.com.
© Press Release 2019Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
